StockData
BillionToOne, Inc. logo

BillionToOne, Inc. (BLLN) company profile

BLLNNasdaqServices-Medical LaboratoriesFiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Nov 4, 2026Score 11/30
$97.50+1.19 (+1.24%)

Close on Nov 17, 2026Market cap $4.60BP/E –Yield –

About BillionToOne

Services-Medical Laboratories, SIC 8071

BillionToOne, Inc. operates as a precision molecular diagnostics company specializing in non-invasive single-molecule next-generation sequencing tests. The organization develops liquid biopsy screening tools utilizing cell-free DNA to assess fetal genetic conditions and evaluate oncology therapy outcomes. Its prenatal portfolio includes the UNITY suite of maternal blood tests, which screen for recessive genetic conditions, chromosomal aneuploidies, microdeletions, and fetal red blood cell antigens. In oncology, the firm offers Northstar Select for solid tumor therapy guidance and Northstar Response for monitoring treatment efficacy and quantifying tumor burden. The company's primary customers include obstetricians, maternal-fetal medicine specialists, oncologists, healthcare systems, and clinical trial partners.

The business delivers its diagnostic screening services across the United States and has secured regulatory clearances for clinical trial testing in select European and Latin American jurisdictions. BillionToOne conducts prospective multi-site clinical evaluations across academic medical centers and healthcare networks, including over 150,000 completed fetal RhD assessments. The provided text does not identify the location of the company's headquarters.

Summary of the business section of BillionToOne's latest annual report, written by StockData.

Company profile

Company

Legal name
BillionToOne, Inc.
Founded
2016
Headquarters
Menlo Park, CA
Address
1035 O'Brien Drive
Phone
(650) 460-2551
Employees
713, Dec 31, 2025
Industry
Services-Medical Laboratories
Incorporated in
Delaware
Fiscal year ends
December 31
Auditor
PricewaterhouseCoopers LLP, Florham Park, New Jersey

Stock & identifiers

Ticker
BLLN
Exchange
Nasdaq
IPO date
Nov 6, 2025
Shares outstanding
47M, Aug 3, 2026
Filer category
Non-accelerated filer<br>Emerging growth company
SEC CIK
2070849
CUSIP
090168105
ISIN
US0901681058
FIGI
BBG00NR7JXT0
Share class FIGI
BBG00NR7JXV7
EIN
81-1082020

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
David TsaoChief Technology Officer, Director2,306,108
Oguzhan AtayChairman and CEO, Director2,601,143
Bosch John Roderick tenSVP of Laboratory Operations16,551
Thomas P. LynchSee Remarks10,700
Shan Riku SakakibaraChief Product Officer196,500
Nancy JoAnn JohnsonSee Remarks18,966
John ListerChief Administrative Officer–
Ross TaylorChief Financial Officer–
Krishna Kittu KolluriDirector1,646,225
Firat IleriDirector3,298,769
Akshay RaiDirector3,582,854
Anthony PaganoDirector7,913
Thomas S. BremnerDirector1,161,734

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryBonusOption awardsOtherTotalvs. prior year
Oguzhan Atay
Chief Executive Officer
$371.81K$136.00K$19.17M$10.59K$19.68M+5205%
David Tsao
President and Chief Technology Officer
$332.94K$113.85K$9.58M$14.00K$10.04M+2632%
John Lister
Chief Administrative Officer
$182.98K$61.21K$3.09M$2.40K$3.36M–

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
Nov 6, 2025
Offer price
$60.00
Securities offered
4,551,100
Gross proceeds
$273.07M
Exchange
Nasdaq
Lock-up ends (est.)
May 5, 2026

“The initial public offering price is $60.00 per share.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Corporate history

Events identified from SEC filings

See a number that looks wrong?